Profile data is unavailable for this security.
About the company
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.
- Revenue in USD (TTM)54.32bn
- Net income in USD4.82bn
- Incorporated2012
- Employees50.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
Acquired company | ABBV:NYQ since announced | Transaction value |
---|---|---|
Cerevel Therapeutics Holdings Inc | 14.27% | 8.62bn |
ImmunoGen Inc | 19.28% | 10.22bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | 54.32bn | 4.82bn | 290.83bn | 50.00k | 60.40 | 28.00 | 21.38 | 5.35 | 2.72 | 2.72 | 30.63 | 5.87 | 0.3972 | 4.75 | 4.85 | 1,086,360.00 | 3.56 | 6.55 | 4.73 | 8.40 | 66.45 | 69.74 | 8.97 | 16.46 | 0.7638 | 9.12 | 0.851 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
Merck & Co Inc | 60.11bn | 365.00m | 317.57bn | 72.00k | 961.35 | 8.45 | 74.74 | 5.28 | 0.1304 | 0.1304 | 23.74 | 14.84 | 0.557 | 2.59 | 6.07 | 834,916.70 | 0.3493 | 7.70 | 0.4548 | 10.29 | 73.53 | 72.26 | 0.6271 | 15.03 | 1.00 | 7.61 | 0.4823 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
Johnson & Johnson | 81.80bn | 18.75bn | 348.86bn | 131.90k | 19.26 | -- | 18.74 | 4.27 | 7.51 | 16.07 | 32.76 | -- | -- | -- | -- | 620,136.40 | -- | 8.93 | -- | 11.96 | 70.22 | 68.17 | 22.92 | 18.86 | -- | -- | -- | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 152.47m | 8.63% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 93.18m | 5.28% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 78.20m | 4.43% |
Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 44.99m | 2.55% |
Geode Capital Management LLCas of 31 Dec 2023 | 37.02m | 2.10% |
JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 33.92m | 1.92% |
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 30.30m | 1.72% |
Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 24.45m | 1.38% |
Norges Bank Investment Managementas of 31 Dec 2023 | 20.84m | 1.18% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 19.37m | 1.10% |